459 related articles for article (PubMed ID: 35264438)
1. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis.
Ma Y; Liu N; Wang Y; Zeng J; Hu YY; Hao W; Shi H; Zhu P; Lv J; Fan W; Wang X
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34845005
[TBL] [Abstract][Full Text] [Related]
4. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
5. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
Strobel SB; Machiraju D; Kälber KA; Hassel JC
Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.
Läubli H; Balmelli C; Kaufmann L; Stanczak M; Syedbasha M; Vogt D; Hertig A; Müller B; Gautschi O; Stenner F; Zippelius A; Egli A; Rothschild SI
J Immunother Cancer; 2018 May; 6(1):40. PubMed ID: 29789020
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.
Wang D; Zhang S; Ding P; Zhao Y; Zhang X; Zhao Q
Iran J Immunol; 2020 Jun; 17(2):167-171. PubMed ID: 32602470
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
[TBL] [Abstract][Full Text] [Related]
12. Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Zhang S; Li J; Xu R; Chen Q; Sun G; Lin Y; Cao Y; Chen Y; Geng C; Teng Y; Nie J; Li X; Xu G; Liu X; Jin F; Fan Z; Luo T; Liu H; Wang FS; Jiang Z
JMIR Public Health Surveill; 2023 Dec; 9():e46009. PubMed ID: 38060302
[TBL] [Abstract][Full Text] [Related]
13. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
[TBL] [Abstract][Full Text] [Related]
14. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
[TBL] [Abstract][Full Text] [Related]
16. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
[TBL] [Abstract][Full Text] [Related]
20. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
